Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive symbols : Bbio save search
BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months
Published: 2024-02-02 (Crawled : 12:00) - globenewswire.com
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: -1.41%
H: 5.51%
C: 3.26%
pharma positive trial results study
BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine
Published: 2024-01-10 (Crawled : 22:00) - globenewswire.com
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: -1.4%
H: 0.08%
C: -0.31%
pharma positive publication results study
BridgeBio Pharma Announces New England Journal of Medicine Publication of Positive Encaleret Proof-of-Concept Phase 2b Results in Patients with Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Published: 2023-10-10 (Crawled : 12:00) - bridgebio.com
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: -0.04%
H: 5.51%
C: 3.67%
pharma positive publication results
BridgeBio Pharma Shares Positive Long-Term Data from an Ongoing Phase 2 Study, which Support the Potential Use of Glycosylated Alpha-dystroglycan (⍺DG) Levels as a Surrogate Endpoint in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
Published: 2023-10-09 (Crawled : 12:00) - bridgebio.com
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 0.0%
H: 1.5%
C: 1.39%
pharma positive ongoing potential
BridgeBio Pharma Announces Positive Feedback from the U.S. FDA and EU EMA on the Regulatory Path for a Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia
Published: 2023-09-06 (Crawled : 12:00) - bridgebio.com
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 0.57%
H: 2.22%
C: -1.01%
fda pharma children achondroplasia positive ema trial
BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at European Society of Cardiology Congress 2023
Published: 2023-08-27 (Crawled : 12:20) - globenewswire.com
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
| Email alert
Add to watchlist
positive cardiology results study
BridgeBio announces consistently positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)
Published: 2023-07-17 (Crawled : 11:00) - globenewswire.com
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 46.87%
H: 28.1%
C: 19.73%
positive results study
BridgeBio Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm/year with No Treatment-related Adverse Events
Published: 2023-03-06 (Crawled : 12:00) - globenewswire.com
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 65.5%
H: 7.78%
C: -8.17%
velocity positive results achondroplasia phase 2
BridgeBio Pharma Announces Positive Interim Results from a Phase 2 Trial of Infigratinib in Achondroplasia Demonstrating an Increase in Annualized Height Velocity of 1.52 cm/year in Children 5 Years of Age and Older, and Adds 5th Cohort to Trial
Published: 2022-07-26 (Crawled : 20:00) - biospace.com/
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 8.43%
H: 0.0%
C: -22.32%
pharma children trial positive results achondroplasia
BridgeBio Pharma Announces Positive Interim Results from a Phase 2 Trial of Infigratinib in Achondroplasia
Published: 2022-07-26 (Crawled : 13:00) - biospace.com/
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 8.43%
H: 0.0%
C: -22.32%
pharma trial positive results phase 2 achondroplasia
BridgeBio Pharma and Sentynl Therapeutics Receive Positive CHMP Opinion for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A
Published: 2022-07-25 (Crawled : 12:00) - prnewswire.com
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 0.59%
H: 8.42%
C: 8.03%
nulibry treatment pharma chmp therapeutics positive
BridgeBio Pharma Announces Positive Phase 1 Data and Phase 2/3 Trial Design for BBP-711, a Potentially Best-In-Class GO Inhibitor for Primary Hyperoxaluria Type 1 (PH1) and Recurrent Kidney Stone Formers
Published: 2022-06-27 (Crawled : 12:00) - biospace.com/
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 0.22%
H: 2.22%
C: 1.3%
bbp-711 pharma kidney trial positive phase 1 potential
BridgeBio Pharma Announces Early Positive Data for BBP-812, its Investigational AAV9 Gene Therapy for Canavan Disease
Published: 2022-06-22 (Crawled : 12:00) - biospace.com/
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: -1.02%
H: 12.96%
C: 8.61%
bbp-812 pharma disease aav9 positive therapy
BridgeBio Pharma Presents Positive Phase 1 Data in Healthy Volunteers, Advancing Development of BBP-671 for Pantothenate Kinase-Associated Neurodegeneration (PKAN) and Organic Acidemias
Published: 2022-05-26 (Crawled : 18:00) - globenewswire.com
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: -0.45%
H: 5.15%
C: 0.3%
bbp-671 pharma positive phase 1
BridgeBio Pharma Affiliate Phoenix Tissue Repair Announces Positive Results from Phase 2 Trial of PTR-01, a Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Published: 2022-05-20 (Crawled : 12:00) - globenewswire.com
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 3.42%
H: 2.83%
C: 2.7%
ptr-01 treatment pharma trial positive therapy
BridgeBio Pharma Announces Positive Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)
Published: 2022-03-14 (Crawled : 12:30) - biospace.com/
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: -1.04%
H: 0.0%
C: 0.0%
phase 2 muscular dystrophy pos positive pharma
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.